Abbott's UroVysion DNA probe assay has been approved by the FDA for use as an aid in initial diagnosis of bladder cancer in patients with hematuria and suspected of having bladder cancer.
Prostate cancer genomic tests show prognostic value for progression, therapy benefit
April 22nd 2024"This preplanned ENACT trial biomarker analysis demonstrates the value of the Decipher score, AR-A score, and PAM50 genomic classifiers in identifying patients undergoing AS who are most likely to benefit from enzalutamide treatment," wrote the authors.